1. known or suspected hypersensitivity to the active substance or to excipients of the drug xc221 or placebo 2. known or suspected hypersensitivity to standard therapy drugs specified in the moh temporary guidelines. 3. lactase deficiency, lactose intolerance, glucose-galactose malabsorption. 4. presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years). 5. presence of autoimmune diseases by the day of criteria assessment or in medical history. 6. neutropenia (0.5 \* 10\^9 /l). 7. exceeding the upper limit of normal for alt and ast by 5 times or more. 8. thrombocytopenia 50000 / mm\^3. 9. pregnancy. 10. lactation. 11. presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe copd, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of ct examination at screening). 12. patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus. 13. heart failure, nyha functional class iii - iv. 14. chronic liver failure stage ii (decompensated) and higher. 15. the need of renal replacement therapy at the time of inclusion of the patient. 16. organ transplantation in medical history. 17. medical history of epilepsy or the need for anticonvulsant therapy. 18. major depressive disorder, anxiety, other mental disorders requiring medical correction. 19. acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening. 20. administration of any antiviral and / or immunomodulatory drugs after the manifestation of covid-19, with the exception of those specified in the moh temporary guidelines. 21. any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization. 22. administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization. 23. administration of vaccines against viral infections within 90 days prior to randomization. 24. patients receiving other experimental drugs, drugs not approved in the russian federation, or participating in other clinical trials within 30 days before screening. 25. patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year. 26. patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study. 27. expected death within 48 hours after randomization. 28. expected hospital discharge within 48 hours of randomization.

1. known or suspected hypersensitivity to the active substance or to excipients of the drug xc221 or placebo 2. known or suspected hypersensitivity to standard therapy drugs specified in the moh temporary guidelines. 3. lactase deficiency, lactose intolerance, glucose-galactose malabsorption. 4. presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years). 5. presence of autoimmune diseases by the day of criteria assessment or in medical history. 6. neutropenia (0.5 \* 10\^9 /l). 7. exceeding the upper limit of normal for alt and ast by 5 times or more. 8. thrombocytopenia 50000 / mm\^3. 9. pregnancy. 10. lactation. 11. presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe copd, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of ct examination at screening). 12. patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus. 13. heart failure, nyha functional class iii - iv. 14. chronic liver failure stage ii (decompensated) and higher. 15. the need of renal replacement therapy at the time of inclusion of the patient. 16. organ transplantation in medical history. 17. medical history of epilepsy or the need for anticonvulsant therapy. 18. major depressive disorder, anxiety, other mental disorders requiring medical correction. 19. acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening. 20. administration of any antiviral and / or immunomodulatory drugs after the manifestation of covid-19, with the exception of those specified in the moh temporary guidelines. 21. any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization. 22. administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization. 23. administration of vaccines against viral infections within 90 days prior to randomization. 24. patients receiving other experimental drugs, drugs not approved in the russian federation, or participating in other clinical trials within 30 days before screening. 25. patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year. 26. patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study. 27. expected death within 48 hours after randomization. 28. expected hospital discharge within 48 hours of randomization.

known or suspected hypersensitivity to the active substance or to excipients of the drug xc221 or placebo known or suspected hypersensitivity to standard therapy drugs specified in the moh temporary guidelines. lactase deficiency, lactose intolerance, glucose-galactose malabsorption. presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years). presence of autoimmune diseases by the day of criteria assessment or in medical history. neutropenia (0.5 * 10^9 /l). exceeding the upper limit of normal for alt and ast by 5 times or more. thrombocytopenia 50000 / mm^3. pregnancy. lactation. presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe copd, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of ct examination at screening). patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus. heart failure, nyha functional class iii - iv. chronic liver failure stage ii (decompensated) and higher. the need of renal replacement therapy at the time of inclusion of the patient. organ transplantation in medical history. medical history of epilepsy or the need for anticonvulsant therapy. major depressive disorder, anxiety, other mental disorders requiring medical correction. acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening. administration of any antiviral and / or immunomodulatory drugs after the manifestation of covid-19, with the exception of those specified in the moh temporary guidelines. any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization. administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization. administration of vaccines against viral infections within 90 days prior to randomization. patients receiving other experimental drugs, drugs not approved in the russian federation, or participating in other clinical trials within 30 days before screening. patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year. patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study. expected death within 48 hours after randomization. expected hospital discharge within 48 hours of randomization.

known or suspected hypersensitivity to the active substance or to excipients of the drug xc221 or placebo known or suspected hypersensitivity to standard therapy drugs specified in the moh temporary guidelines. lactase deficiency, lactose intolerance, glucose-galactose malabsorption. presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years). presence of autoimmune diseases by the day of criteria assessment or in medical history. neutropenia (0.5 * 10^9 /l). exceeding the upper limit of normal for alt and ast by 5 times or more. thrombocytopenia 50000 / mm^3. pregnancy. lactation. presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe copd, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of ct examination at screening). patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus. heart failure, nyha functional class iii - iv. chronic liver failure stage ii (decompensated) and higher. the need of renal replacement therapy at the time of inclusion of the patient. organ transplantation in medical history. medical history of epilepsy or the need for anticonvulsant therapy. major depressive disorder, anxiety, other mental disorders requiring medical correction. acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening. administration of any antiviral and / or immunomodulatory drugs after the manifestation of covid-19, with the exception of those specified in the moh temporary guidelines. any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization. administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization. administration of vaccines against viral infections within 90 days prior to randomization. patients receiving other experimental drugs, drugs not approved in the russian federation, or participating in other clinical trials within 30 days before screening. patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year. patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study. expected death within 48 hours after randomization. expected hospital discharge within 48 hours of randomization.

1. known or suspected hypersensitivity to the active substance or to excipients of the drug xc221 or placebo 2. known or suspected hypersensitivity to standard therapy drugs specified in the moh temporary guidelines. 3. lactase deficiency, lactose intolerance, glucose-galactose malabsorption. 4. presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years). 5. presence of autoimmune diseases by the day of criteria assessment or in medical history. 6. neutropenia (0.5 * 10^9 /l). 7. exceeding the upper limit of normal for alt and ast by 5 times or more. 8. thrombocytopenia 50000 / mm^3. 9. pregnancy. 10. lactation. 11. presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe copd, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of ct examination at screening). 12. patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus. 13. heart failure, nyha functional class iii - iv. 14. chronic liver failure stage ii (decompensated) and higher. 15. the need of renal replacement therapy at the time of inclusion of the patient. 16. organ transplantation in medical history. 17. medical history of epilepsy or the need for anticonvulsant therapy. 18. major depressive disorder, anxiety, other mental disorders requiring medical correction. 19. acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening. 20. administration of any antiviral and / or immunomodulatory drugs after the manifestation of covid-19, with the exception of those specified in the moh temporary guidelines. 21. any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization. 22. administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization. 23. administration of vaccines against viral infections within 90 days prior to randomization. 24. patients receiving other experimental drugs, drugs not approved in the russian federation, or participating in other clinical trials within 30 days before screening. 25. patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year. 26. patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study. 27. expected death within 48 hours after randomization. 28. expected hospital discharge within 48 hours of randomization.

1. known or suspected hypersensitivity to the active substance or to excipients of the drug xc221 or placebo 2. known or suspected hypersensitivity to standard therapy drugs specified in the moh temporary guidelines. 3. lactase deficiency, lactose intolerance, glucose-galactose malabsorption. 4. presence or suspicion of oncological diseases by the day of criteria assessment or in medical history (within the last 2 years). 5. presence of autoimmune diseases by the day of criteria assessment or in medical history. 6. neutropenia (0.5 * 10^9 /l). 7. exceeding the upper limit of normal for alt and ast by 5 times or more. 8. thrombocytopenia 50000 / mm^3. 9. pregnancy. 10. lactation. 11. presence of serious lung diseases, including, but not limited to the following diseases: moderate and severe bronchial asthma, severe and extremely severe copd, interstitial lung disease, pulmonary hypertension, pulmonary fibrosis, surgical interventions on the lungs, tuberculosis (including suspicion of tuberculosis based on the results of ct examination at screening). 12. patients with type 1 diabetes mellitus and / or decompensated type 2 diabetes mellitus. 13. heart failure, nyha functional class iii - iv. 14. chronic liver failure stage ii (decompensated) and higher. 15. the need of renal replacement therapy at the time of inclusion of the patient. 16. organ transplantation in medical history. 17. medical history of epilepsy or the need for anticonvulsant therapy. 18. major depressive disorder, anxiety, other mental disorders requiring medical correction. 19. acute cerebrovascular accident, stroke or transient ischemic attack within 90 days before screening. 20. administration of any antiviral and / or immunomodulatory drugs after the manifestation of covid-19, with the exception of those specified in the moh temporary guidelines. 21. any immunosuppressive therapy (including tocilizumab / sarilumab) within 90 days prior to randomization, or the need of immunosuppressive therapy at the time of randomization. 22. administration of systemic glucocorticosteroids within 90 days prior to randomization, or the need of systemic glucocorticosteroids at the time of randomization. 23. administration of vaccines against viral infections within 90 days prior to randomization. 24. patients receiving other experimental drugs, drugs not approved in the russian federation, or participating in other clinical trials within 30 days before screening. 25. patients abusing alcohol or psychotropic drugs and other drugs by the day of criteria assessment or during the last year. 26. patients with other serious, unstable, or clinically significant medical or psychological conditions that, in the opinion of the investigator, may preclude the patient's participation in the study. 27. expected death within 48 hours after randomization. 28. expected hospital discharge within 48 hours of randomization.